Anteris screens attractively valued with a favorable 2.01 risk/reward setup and improving momentum, but weak business quality - cash burn, a failing Rule of 40 score, a low Piotroski score, and a four-quarter earnings miss streak - argues the cheapness could be a value trap rather than a genuine opportunity.
Thesis pillars
- Favorable Momentum Asymmetry→Stable
- Attractive Valuation→Stable
- Cash Burning Weak Quality→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Feb 26, 2026
Anteris Technologies Global Cor (AVR) Stock Analysis
Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $6.10: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 10.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.50; Below-average business quality.
Anteris Technologies is a clinical-stage structural heart company developing the DurAVR THV System, a biomimetic, single-piece transcatheter aortic valve designed to treat aortic stenosis by replicating normal blood flow. More than 130 patients have been implanted worldwide as... Read more
Sell if holding. Engine safety override at $6.10: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 10.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.4/10, moderate confidence.
Passes 4/8 gates (positive momentum, favorable risk/reward ratio, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: speculative.
About Anteris Technologies Global Cor
About Anteris Technologies Global Cor
Anteris Technologies has implanted its DurAVR THV System, a biomimetic single-piece transcatheter aortic valve, in more than 130 patients worldwide as of December 2025, and in November 2025 the FDA granted Investigational Device Exemption approval for a staged enrollment of the first 200 patients in its global pivotal PARADIGM Trial. The trial began enrolling in Denmark in October 2025 after Anteris secured its first European regulatory approval, with North America and Europe together representing the large majority of the roughly $12.4 billion combined 2028 TAVR and valve-in-valve market opportunity FMI projects.
As a development-stage company, Anteris currently generates only small amounts of revenue, insufficient to cover its research, development, and operating costs, and recorded a $94.2 million net loss in 2025 against a $370.5 million accumulated deficit. The DurAVR THV's core technology is ADAPT, a proprietary anti-calcification process that converts bovine pericardial tissue into a single-piece collagen bioscaffold, paired with the balloon-expandable ComASUR delivery system for precise commissural alignment; Anteris owns 47 active patents covering the valve, delivery system, sterilization, and packaging. The company competes against Edwards Lifesciences and Medtronic, the dominant TAVR suppliers, and states that no competitor currently has a single-piece tissue TAVR either commercially available or publicly disclosed in development. Anteris also holds a 30% interest in v2vmedtech, a separate developer of mitral and tricuspid valve-repair devices, funded in part through a 2023 development agreement.
Show full overview
Anteris's near-term value hinges almost entirely on a single clinical readout: the DurAVR THV System is described in the 10-K as the company's lead product, and the filing warns that if development cannot be completed or the device fails to gain approval, it could prevent Anteris from ever achieving profitability, with no other clinical-stage product positioned to offset that outcome. The PARADIGM Trial's initial 200-patient U.S. cohort, still enrolling under a staged FDA IDE, is the gating event for that single-asset bet. Underscoring capital discipline while spending is concentrated on DurAVR, in April 2026 Anteris notified v2vmedtech that it would discontinue further development contributions under their 2023 agreement, triggering a $400,000 break fee and ending Anteris's funding obligations to that side project.
See also: Healthcare · Medical Devices
From Anteris Technologies Global Cor's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Anteris Technologies Global Cor
Latest news
- NEWS Anteris Technologies Announces Upcoming Data Presentation for Medium-Size DurAVR THV at TCT 2026 — fiscal.ai Oct 27, 2026 positive
- NEWS Anteris Technologies To Present First 30-Day Clinical And Hemodynamic Outcomes For Its Medium-Size DurAVR Transcatheter — benzinga Oct 27, 2026 positive
- NEWS Anteris Technologies Receives German Regulatory Clearance for PARADIGM Trial — fiscal.ai Oct 20, 2026 positive
- NEWS Reported Earlier, Anteris Secures German Regulatory Clearance To Expand PARADIGM Trial Comparing DurAVR THV With Commerc — benzinga Oct 20, 2026 positive
- NEWS Cantor Fitzgerald Reiterates Overweight on Anteris Technologies Glb, Maintains $15 Price Target — benzinga Oct 14, 2026 positive
Generated 2026-10-29T11:48:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineDurAVR® THV System10-K Item 1A: 'our lead product, DurAVR® THV System, is undertaking clinical trials designed to provide the primary clinical evidence'
Material Events(8-K, last 90d)
- 2026-04-29Item 1.02MEDIUMAnteris notified v2vmedtech on April 28, 2026 that it would discontinue further development contributions under their April 2023 Contribution and Stock Purchase Agreement, following completion of Stage 1. Anteris owes a $400,000 break fee; v2v may elect to buy back Anteris's equity stake or reduce it to a capped minority position.SEC filing →
- 2026-05-13Item 5.02LOWBoard appointed Susan Knight (Class I director, Audit and Risk Committee) and Stephen Denaro (Class II director) effective May 11-12, 2026. Routine board expansion, not a departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.10: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.4/10 and A.R:R 10.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 2.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.67. Score 6.4/10, moderate confidence.
Analyst target: $11.90 (+95.1% upside). Prior stop was $5.67. Stop-loss: $5.67.
Concentration risk — Pipeline: DurAVR® THV System; Quality below floor (3.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin -3.1%), Material insider selling (4 sells, 0.16% of cap).
Anteris Technologies Global Cor trades at a P/E of N/A (forward -5.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
8 analysts cover AVR with a consensus score of 4.0/5. Average price target: $14.
What does Anteris Technologies Global Cor do?Anteris Technologies is a clinical-stage structural heart company developing the DurAVR THV System, a biomimetic,...
Anteris Technologies is a clinical-stage structural heart company developing the DurAVR THV System, a biomimetic, single-piece transcatheter aortic valve designed to treat aortic stenosis by replicating normal blood flow. More than 130 patients have been implanted worldwide as of December 2025, and the company is running its global pivotal PARADIGM Trial under an FDA Investigational Device Exemption covering an initial 200 patients. Anteris reported a $94.2 million net loss in 2025 against a $370.5 million accumulated deficit.